Good or excellent response Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response Global assessment of symptom scores compared with placebo (low certainty).
1 finding from 1 review
Complete cessation of urticaria Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete cessation of urticaria Global assessment of symptom scores compared with cetirizine 10 mg (low certainty).
1 finding from 1 review
Complete suppression of urticaria: intermediate‐term duration of intervention · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete suppression of urticaria: intermediate‐term duration of… compared with desloratadine 5 mg (low certainty).
1 finding from 1 review
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response: intermediate‐term duration of… compared with desloratadine 5 mg (low certainty).
1 finding from 1 review
Complete cessation of urticaria: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
It is very uncertain whether loratadine 10 mg changes complete cessation of urticaria: intermediate‐term duration of… compared with mizolastine 10 mg (very low certainty).
1 finding from 1 review
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response: intermediate‐term duration of… compared with mizolastine 10 mg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with mizolastine 10 mg (low certainty).
1 finding from 1 review
Proportion of participants with at least 50% improvement in QoL: intermediate‐term duration of intervention Symptom score reducing index (SSRI) · patients with chronic spontaneous urticaria
It is very uncertain whether loratadine 10 mg changes proportion of participants with at least 50% improvement in QoL:… compared with mizolastine 10 mg (very low certainty).
1 finding from 1 review
Complete cessation of urticaria: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete cessation of urticaria: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Good or excellent response: intermediate‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in good or excellent response: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Complete suppression of urticaria: short‐term duration of intervention Global assessment of symptom scores · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete suppression of urticaria: short‐term duration of… compared with hydroxyzine 25 mg (low certainty).
1 finding from 1 review
Pruritus · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Physician‐assessed changes in clinical signs · adults with eczema
1 finding from 1 review
Secondary outcome: quality of life · adults with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: clinical flare · adults with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · adults with eczema
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
Secondary outcome 1. Physician‐assessed clinical signs Number for whom treatment success was judged as good or very good · adults with eczema
Loratadine 10 mg/d showed no clear difference in secondary outcome 1. Physician‐assessed clinical signs Number for… compared with placebo (2‐week intervention) (low certainty).
1 finding from 1 review